BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18449006)

  • 21. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
    Georgoulias V; Kourousis C; Kakolyris S; Androulakis N; Dimopoulos MA; Papadakis E; Kotsakis T; Vardakis N; Kalbakis K; Merambeliotakis N; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-61-S12-66. PubMed ID: 9331124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
    Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
    Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
    Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
    Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
    Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
    Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
    Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
    Choy H; Jain AK; Moughan J; Curran W; Whipple G; Demas WF; Ettinger DS
    J Thorac Oncol; 2009 Jan; 4(1):80-6. PubMed ID: 19096311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
    Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial.
    Hirsh V; Whittom R; Ofiara L; Desjardins P; Ayoub J; Charpentier D; Small D; Pintos J; Langleben A
    Cancer; 2003 May; 97(9):2242-7. PubMed ID: 12712478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
    Tsimberidou AM; Ye Y; Wheler J; Naing A; Hong D; Nwosu U; Hess KR; Wolff RA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):955-63. PubMed ID: 23377373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of nab-paclitaxel plus sunitinib: analysis of three cases.
    Dudek AZ; Nguyen S
    Anticancer Res; 2008; 28(5B):3099-105. PubMed ID: 19031964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
    Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
    J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.